General Relativistic Effect of Gravitomagnetic Charge on Pulsar Magnetosphere and Particle Acceleration in a Polar Cap

We study magnetospheric structure surrounding rotating magnetized neutron star with nonvanishing NUT (Newman-Tamburino-Unti) parameter. For the simplicity of calculations Goldreich-Julian charge density is analyzed for the aligned neutron star with zero inclination between magnetic field, gravitomagnetic field and rotation axis. From the system of Maxwell equations in spacetime of slowly rotating NUT star, second-order differential equation for electrostatic potential is derived. Analytical solution of this equation indicates the general relativistic modification of an accelerating electric field and charge density along the open field lines by the gravitomagnetic charge. The implication of this effect to the magnetospheric energy loss problem is underlined. In the second part of the paper we derive the equations of motion of test particles in magnetosphere of slowly rotating NUT star. Then we analyze particle motion in the polar cap and show that NUT parameter can significantly change conditions for particle acceleration.Comment: 21 pages, 6 figures, accepted for publication in Ap

External Electromagnetic Fields of a Slowly Rotating Magnetized Star with Gravitomagnetic Charge

We study Maxwell equations in the external background spacetime of a slowly rotating magnetized NUT star and find analytical solutions for the exterior electric fields after separating the equations of electric field into angular and radial parts in the lowest order approximation. The star is considered isolated and in vacuum, with dipolar magnetic field aligned with the axis of rotation. The contribution to the external electric field of star from the NUT charge is considered in detail.Comment: 6 pages, 2 figures, accepted for publication in Astrophysics and Space Scienc

Personalized medicine in the treatment of inflammatory bowel diseases

Personalized medicine (personalized medicine, individualized medicine) represents the totality of methods of prevention of a pathological condition, diagnosis and treatment in the event of its occurrence, based on individual patient characteristics. Such individual characteristics include genetic, epigenetic, and transcript, proteome, metabolomic and metagenomic markers, as well as a set of variable phenotypic traits - both of the patient's body and its separate tissues or cells. For example, treatment of inflammatory bowel diseases (IBD) can most clearly show the importance of applying personalized approaches. Currently in the treatment of patients with IBD paid great attention to genetic studies, monitoring of the concentration of the biological drugs and the level of antibodies to them, the role of microbiota as a predictor of effectiveness of therapy of IBD. Used clinical, laboratory, instrumental methods, as well as new biomarkers to assess the forecasting efficiency of conservative therapy in IBD patient. In the future treatment of patients with IBD will include a number of personalized data in order to better predict outcomes of the disease in each patient and more accurately select the appropriate treatment regimen

Geodesics of electrically and magnetically charged test particles in the Reissner-Nordstr\"om space-time: analytical solutions

We present the full set of analytical solutions of the geodesic equations of charged test particles in the Reissner-Nordstr\"om space-time in terms of the Weierstra{\ss} $\wp$, $\sigma$ and $\zeta$ elliptic functions. Based on the study of the polynomials in the $\vartheta$ and $r$ equations we characterize the motion of test particles and discuss their properties. The motion of charged test particles in the Reissner-Nordstr\"om space-time is compared with the motion of neutral test particles in the field of a gravitomagnetic monopole. Electrically or magnetically charged particles in the Reissner-Nordstr\"om space-time with magnetic or electric charges, respectively, move on cones similar to neutral test particles in the Taub-NUT space-times

The Real Scalar Field Equation for Nariai Black Hole in the 5D Schwarzschild-de Sitter Black String Space

The Nariai black hole, whose two horizons are lying close to each other, is an extreme and important case in the research of black hole. In this paper we study the evolution of a massless scalar field scattered around in 5D Schwarzschild-de Sitter black string space. Using the method shown by Brevik and Simonsen (2001) we solve the scalar field equation as a boundary value problem, where real boundary condition is employed. Then with convenient replacement of the 5D continuous potential by square barrier, the reflection and transmission coefficients ($R, T$) are obtained. At last, we also compare the coefficients with usual 4D counterpart.Comment: 10 pages,6 figures.To appear in Int. J. Mod. Phys.

Particle Motion and Electromagnetic Fields of Rotating Compact Gravitating Objects with Gravitomagnetic Charge

The exact solution for the electromagnetic field occuring when the Kerr-Taub-NUT compact object is immersed (i) in an originally uniform magnetic field aligned along the axis of axial symmetry (ii) in dipolar magnetic field generated by current loop has been investigated. Effective potential of motion of charged test particle around Kerr-Taub-NUT gravitational source immersed in magnetic field with different values of external magnetic field and NUT parameter has been also investigated. In both cases presence of NUT parameter and magnetic field shifts stable circular orbits in the direction of the central gravitating object. Finally we find analytical solutions of Maxwell equations in the external background spacetime of a slowly rotating magnetized NUT star. The star is considered isolated and in vacuum, with monopolar configuration model for the stellar magnetic field.Comment: 18 pages, 6 figures, new results in section 2 added, section 3 is revised, 3 references are adde

Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice

Aim. To assess the efficacy and tolerance of certolizumab pegol (CP) in patients with Crohn's disease (CD) treated in the Department of inflammatory bowel diseases of the A.S. Loginov Moscow Clinical Research Center and to determine the predictors of response to therapy. Materials and methods. All patients with CD who had received the treatment of CP were observed prospectively for at least 6 months or until the date of discontinuation of the drug. The effectiveness of the study was assessed response to therapy by the 6th week, maintaining the clinical response (6th and 26th weeks), the dynamics of endoscopic parameters by the 10th and 54th week of therapy, long-term maintenance of remission, healing fistula. Used univariant and multivariate analyses of predictors of response to treatment. Results and discussion. The study included 39 patients: 12 (30.7%) men and 27 (69.3%) female, the average duration of observation was 104 weeks. The interdepartmental range was in the range from 28 to 158 weeks. Clinical improvement occurred in 38 out of 39 (97.4 %) patients with CD. Comparative analysis of response to treatment with CP have bionaive patients previously treated with another inhibitor of TNF-α. In the group of bionaive response to therapy in a month, 6 months and at the end of the observation period occurred at 100.0%, 95.0% and 95.0%, respectively. In the group of patients previously treated with GSI, the response rate was about 94.4 %, 88.9 % and 77.7% week 54 endoscopic response and endoscopic remission was maintained in 46,2% and 30,1% patients, complete healing of the mucosa on the background of maintenance therapy, CP, was preserved in 20.5% of patients with Crohn's disease. In the group of patients with perianal lesions (n=13) complete closure of all fistulas was observed in 5 (38.6 %) patients, partial response was observed in 4 patients (30,7%) patients, in 4 (30.7 %) closure of fistulas occurred. The frequency of adverse events was 0 cases (0.0%). The dose escalation was required in 3 patients (7,7%) patients with CD. Dose escalation in our study required patients with high initial CDAI and previous inefficiencies of the other two inhibitors of TNF-α. Reliable predictors of secondary loss of response and need for dose escalation of the drug has been the continued level of CRP >5 mg/l after 2 weeks initiation of therapy CP and smoking. Conclusion. The obtained results demonstrate the efficacy and tolerability profile of CP appropriate for long-term CD therapy in real clinical practice

Stem Cell Therapy for Perianal Crohn’s Disease

Aim. To compare the effectiveness of the effect of combination therapy (local and systemic administration) with bone marrow mesenchymal stromal cells (MSC), anticlitokine therapy with infliximab (IFX), and antibiotic (AB)/immunosuppressive (IS) therapy on the frequency of healing of simple perianal fistulas in Crohn's disease. Materials and methods. In our study, the 1-st group of patients aged 19 to 58 years (Me-29) (n = 12) received MSCs culture systemically according to the scheme and locally. The 2-nd group of patients with CD (n = 10) from 20 to 68 years old (Me-36) received anticytokine therapy with infliximab (IFX) according to the scheme. The 3-d group of patients with CD (n=14) from 20 to 62 years old (Me-28) received antibiotics (AB) and immunosuppressors (IS). Efficacy was assessed by the index of perianal activity of Crohn's disease (PCDAI) and the frequency of relapses. Results. After 12 weeks among patients of the 1-st group, healing of simple fistulas was noted in 8/12 patients (66.6%), in the 2-nd group in 6/10 (60.0%) In the 3-d group, in 1/14 patients (7.14%). After 6 months in the 1-st group of patients, healing of simple fistulas was preserved in 8/12 (66.6%), in the 2-nd group - in 6/10 (60.0%). In the 3-d group - in 1/14 patients (7.14%). After 12 months in the 1-st group, healing of simple fistulas was preserved in 7/12 (58.3%), in the second group - in 6/10 (60.0%). In the 3-d group - in 2/14 patients (14.3%). After 24 months, among the patients of the 1-st group, fistula closure was maintained in 5/12 patients (41.6%), in the 2-nd group - in 4/10 (40.0%). In the 3-d group - in 0/14 patients (0.0%). Conclusion. Combined cellular and anticytokine therapy of CD with perianal lesions significantly contributes to the more frequent and prolonged closure of simple fistulas, as compared to antibiotics/immunosuppressors, and to a decrease in the frequency of recurrence of the disease

Mesenchymal stromal cells of bone marrow and azathioprine in Crohn's disease therapy

Crohn's disease (CD) is a chronic, recurring disease of the gastrointestinal tract of unclear etiology. One of the new approaches to CD therapy is the use of the possibilities of stem cells, in particular, mesenchymal stromal cells (MSCs). Currently, the use of MSC in clinical practice for the treatment of chronic inflammatory and autoimmune diseases is being studied in patients who receive concomitant therapy with other immunomodulatory medications. Aim. To evaluate the effectiveness of MSCs therapy in patients with CD receiving azathioprine (AZA). Materials and methods. The study included 34 patients with inflammatory (luminal) form of CD. The 1st group of patients (n=15) received anti-inflammatory therapy using MSCs culture in combination with AZA. The 2nd group (n=19) received MSCs without AZA. The severity of the attack was assessed in points in accordance with the of Crohn's disease activity index (CDAI). Immunoglobulins (IgA, IgG, IgM), interleukins (IL) 1β, 4, 10, tumor necrosis factor-α (TNF-α), interferon-γ (INF-γ), transforming growth factor-1β (TGF-1β), C-reactive protein (CRP), platelets and erythrocyte sedimentation rate (ESR) at 2, 6 and 12 months from the beginning of MSCs therapy. Results. The initial mean CDAI in the 1st group was 337.6±17.1 points, in the 2nd group - 332.7±11.0 points (p=0.3). In both groups of patients there was a significant decrease in CDAI after 2 months. From the beginning of therapy MSCs: in the 1st group to 118.9±12.4 points, in the 2nd - 120.3±14.1 points (p=0.7), after 6 months - 110.3±11.1 and 114.3±11.8 points (p=0.8), respectively. After 12 months CDAI in the 1st group was 99.9±10.8 points, in the 2nd group it was 100.6±12.1 points (p=0.8). The level of IgA, IgG, IgM was significantly lower in the group of patients with a longer history of the disease and long-term ASA. After the introduction of MSC in both groups of patients with BC, there was a tendency for the growth of pro - and anti-inflammatory cytokines, with a significantly lower level of pro-inflammatory cytokines - INF-γ, TNF-α, IL-1β - in the 1st group, indicating potentiation of the immunosuppressive effect of MSCs and AZA, which provides a more pronounced anti-inflammatory effect. Conclusion. Transplantation of MSCs promotes an increase in the serum of patients with CD initially reduced concentration of IG, cytokines and restoring their balance as the onset of clinical remission. The combination with AZA has a more pronounced anti-inflammatory effect